DMA vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DMA exhibits severe financial weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in operational efficiency and financial health. The company reports 0.00% across all profit margins and lacks essential valuation data (Altman Z-Score, Graham Number), making it impossible to establish a fundamental floor. While the 17.13% dividend yield is superficially attractive, the 0% payout ratio and low dividend strength score (40/100) suggest a potential yield trap or return of capital. Technical trends are completely bearish (0/100), and recent price action shows a consistent short-term decline.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
DMA vs JPM: Head-to-Head Comparison
This page compares Destra Multi-Alternative Fund (DMA) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.